Company / Cash per Share
Jazz Pharmaceuticals Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$22.96
FY2025
5-year range
$10.53 / $38.76
FY2021-FY2025
Trend
-40.8%
vs FY2024
Sector context
#7 of 205
Health Care
What the data says
Among 205 Health Care companies, Jazz Pharmaceuticals is in the top 3% for cash per share. Cash per Share has fluctuated over the past 10 years, ranging from $5.26 in FY2018 to $38.76 in FY2024.
Based on SEC 10-K filings.
22.96 in FY2025 with a 5-year CAGR of +4.0%. Top quartile in the Health Care sector.
Declined from $23.83 to $22.96 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +17.1%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 205This company $22.96 Sector average $67.98
▼
-66.2% below sector average
Key checks
Key Insights
- In FY2025, cash per share decreased 40.8% year-over-year.
- Ranks #7 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2024.
- Lowest cash per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.96 | -40.8% |
| FY2024 | $38.76 | +62.7% |
| FY2023 | $23.83 | +66.6% |
| FY2022 | $14.30 | +35.8% |
| FY2021 | $10.53 | -44.1% |
| FY2020 | $18.84 | +70.6% |
| FY2019 | $11.05 | +110.1% |
| FY2018 | $5.26 | -18.5% |
| FY2017 | $6.45 | -42.2% |
| FY2016 | $11.16 | -31.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026